Author is bullish on Inventiva (IVA) citing its oral Phase 3 MASH drug lanifibranor with impressive results and potential to be the second approved drug in a huge MASH market, comparing it to ABIVAX.
IVA — LONG The author is bullish on Inventiva, which presented at JPM Healthcare 2026 and is in the final stages of Phase 3 trials for its MASH drug lanifibranor. The author notes that unlike Madrigal's drug, lanifibranor is taken orally and its results are impressive. The author believes it could become the second approved drug in the huge MASH market and that the company is completely under the radar, similar to ABIVAX previously.
They are in the final stages of Phase 3 trials for their MASH drug: lanifibranor.
Unlike Madrigal's drug, it is taken orally, and its results are impressive.
It could become the second approved drug in the huge MASH market.
I'll let you do your own research, but this company is completely under the radar, a bit like ABIVAX back in the day, and we saw how that turned out.
I'm in!
This Reddit post, published January 13, 2026, features u/Beautiful-Cod-3414 discussing IVA. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Beautiful-Cod-3414 · Tickers: IVA